The collaboration will combine Rondo’s proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory bispecific antibodies to treat solid tumors.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Congruence Therapeutics Inc. to generate novel small-molecule correctors against multiple protein targets in the oncology area.

Ipsen SA and Biomunex Pharmaceuticals SAS have signed an exclusive global licensing agreement for BMX-502, a preclinical novel T-cell engager with potential for solid tumors. BMX-502 is a bispecific antibody that engages and activates mucosal-associated invariant T (MAIT) cells and targets the GPC3 tumor antigen, to kill cancer cells.

The collaboration aims to identify a small molecule that targets mutant androgen receptor (AR) mRNA splicing and causes selective destruction of the disease-causing mRNA.

Sarepta Therapeutics Inc. has signed a licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. to obtain exclusive global rights to multiple clinical, preclinical and discovery-stage programs for rare genetic diseases of the muscle, central nervous system (CNS) and the lungs. The deal includes ARO-DUX4, ARO-DM1, ARO-MMP7 and ARO-ATXN2.

Oxford Nanopore Technologies Ltd. has established a new collaboration with UK Biobank to create the world’s first comprehensive, large-scale epigenetic dataset. The project will utilize Oxford Nanopore’s DNA/RNA sequencing technology to map the epigenome of 50,000 blood samples from UK Biobank to unlock insights into disease mechanisms, with the aim of improving patient outcomes.